Table 3.
Patient cohort demographics and medication use. NLRP3 inflammasome testing was conducted in adolescent patients with mood disorders (n = 7), including two adolescents with bipolar spectrum disorders and five adolescents with depressive disorders. Abbreviations: selective-serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI).
| Total Mood Disorders | Bipolar Disorders | Depressive Disorders | ||||
|---|---|---|---|---|---|---|
| (n = 7) | (n = 2) | (n = 5) | ||||
| Age, M (SD) | 16.9 (1.68) | 17.5 (0.71) | 16.6 (1.95) | |||
| Sex, N (%) | ||||||
| Male | 2 (29%) | 0 (0%) | 2 (40%) | |||
| Female | 5 (71%) | 2 (100%) | 3 (60%) | |||
| Medication, N (%) | ||||||
| SSRI | 4 (57%) | 0 (0%) | 4 (80%) | |||
| SNRI | 1 (14%) | 1 (50%) | 0 (0%) | |||
| None | 2 (29%) | 1 (50%) | 1 (20%) | |||